|Bid||6.40 x 2900|
|Ask||6.60 x 2200|
|Day's Range||5.95 - 6.67|
|52 Week Range||2.62 - 16.38|
|Beta (3Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sintx Technologies (NASDAQ: SINT ) shares ...
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 25.81% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...